Page 353 - Binder2

● Deflect pressure from payers, patients, or public
health advocates demanding lower-cost solutions.
● Continue extracting profit from old systems while
the new ones struggle for legitimacy.

This isn’t a failure of imagination. It’s a calculated business
decision.

Because the longer edible biologics remain trapped in a
regulatory gray zone, the longer traditional biologics
remain the only viable option on the market.

And in a game where time equals revenue, delay is
profitable.

4. Their Systems Aren’t Built for Simplicity

For decades, the pharmaceutical industry has scaled by
embracing complexity. Complexity in manufacturing.
Complexity in compliance. Complexity in distribution. The
very architecture of Big Pharma is built to handle this
complexity—and to leverage it as a barrier to competition.

Billions of dollars have been poured into centralized
manufacturing campuses featuring:

● Cleanroom environments with HEPA filtration
systems and pressurized airlocks.
● Automated sterile fill-finish lines operating under
21 CFR Part 11 standards.
● Temperature-monitored warehouses and fleets of
refrigerated trucks.
● Entire compliance divisions focused on validation,
inspection readiness, and electronic batch records.

351